Allergy and Immunology · Los Angeles, CA
NPI
1407130636
Since 2011
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1520 San Pablo St Ste 1000
Los Angeles, CA, 90033
Phone (323) 442-5100
Groups this clinician bills Medicare through
Medicare paid, 2024
$58K
1,217 services
Medicare patients, 2024
189
Average age 62
Drug cost, 2024
$2.6M
2,773 prescriptions
Company payments, 2025
$18.28
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shijun C Xi was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 306 times for 127 patients. In total Shijun C Xi billed 1,217 services in 22 codes, and Medicare paid $58K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-11-27.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 306 | 127 | $13.37 | $4,092 |
| 99215 Office E&M - Established | Office | 150 | 72 | $119.19 | $18K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 138 | 91 | $13.29 | $1,833 |
| 99214 Office E&M - Established | Office | 115 | 62 | $79.58 | $9,151 |
| 99213 Office E&M - Established | Facility | 85 | 54 | $54.15 | $4,603 |
| 99213 Office E&M - Established | Office | 71 | 56 | $55.42 | $3,935 |
| 99215 Office E&M - Established | Facility | 61 | 46 | $107.56 | $6,561 |
| 99214 Office E&M - Established | Facility | 58 | 46 | $71.38 | $4,140 |
| 94010 Pulmonary Function Testing | Facility | 35 | 22 | $6.30 | $221 |
By year: 2022 $49K for 653 services; 2023 $49K for 856 services; 2024 $58K for 1,217 services.
Medicare prescription drug claims, 2024
In 2024, the drug Shijun C Xi prescribed most often to Medicare patients was Diphenhydramine Hcl, with 281 prescriptions and refills. In total Shijun C Xi wrote 2,773 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diphenhydramine Hcl Generic | 281 | 281 | Under 11 | $20K |
| Quzyttir Cetirizine Hcl | 163 | 163 | Under 11 | $361K |
| Montelukast Sodium Generic | 163 | 392 | 44 | $2,412 |
| Cromolyn Sodium Generic | 152 | 179 | 34 | $105K |
| Famotidine Generic | 148 | 307 | 34 | $2,432 |
| Famotidine Famotidine/Pf | 106 | 106 | Under 11 | $5,905 |
| Sodium Chloride 0.9 % Sodium Chloride | 101 | 101 | Under 11 | $1,610 |
| Spiriva Respimat Tiotropium Bromide | 97 | 138 | 22 | $55K |
| Epinephrine Generic | 93 | 105 | 44 | $16K |
| Breyna Budesonide/Formoterol Fumarate | 92 | 93 | 21 | $11K |
| Magnesium Sulfate Generic | 86 | 86 | Under 11 | $995 |
| Xolair Omalizumab | 64 | 69 | Under 11 | $486K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 62 | 62 | 24 | $1,549 |
| Dupixent Syringe Dupilumab | 59 | 59 | Under 11 | $299K |
| Prednisone Generic | 58 | 91 | 23 | $322 |
Brand drugs: - claims; generic drugs: 1,581 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shijun C Xi $18.28 ($18.28 in general payments such as food, travel and fees) from 1 company. The largest payer was GlaxoSmithKline, LLC. with $18.28.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 1 | $18.28 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.